TN2017000468A1 - TREATMENT OF BETA-THALASSEMIA USING ACTRIl LIGAND TRAPS. - Google Patents
TREATMENT OF BETA-THALASSEMIA USING ACTRIl LIGAND TRAPS.Info
- Publication number
- TN2017000468A1 TN2017000468A1 TNP/2017/000468A TN2017000468A TN2017000468A1 TN 2017000468 A1 TN2017000468 A1 TN 2017000468A1 TN 2017000468 A TN2017000468 A TN 2017000468A TN 2017000468 A1 TN2017000468 A1 TN 2017000468A1
- Authority
- TN
- Tunisia
- Prior art keywords
- thalassemia
- beta
- actril
- treatment
- ligand traps
- Prior art date
Links
- 208000005980 beta thalassemia Diseases 0.000 title abstract 2
- NRXQIUSYPAHGNM-UHFFFAOYSA-N ioxynil Chemical compound OC1=C(I)C=C(C#N)C=C1I NRXQIUSYPAHGNM-UHFFFAOYSA-N 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
- 239000003112 inhibitor Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 230000011664 signaling Effects 0.000 abstract 2
- 238000007920 subcutaneous administration Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562161136P | 2015-05-13 | 2015-05-13 | |
| US201562173836P | 2015-06-10 | 2015-06-10 | |
| US201562243457P | 2015-10-19 | 2015-10-19 | |
| PCT/US2016/031999 WO2016183280A1 (en) | 2015-05-13 | 2016-05-12 | Treatment of beta-thalassemia using actrii ligand traps |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TN2017000468A1 true TN2017000468A1 (en) | 2019-04-12 |
Family
ID=57248528
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TNP/2017/000468A TN2017000468A1 (en) | 2015-05-13 | 2016-05-12 | TREATMENT OF BETA-THALASSEMIA USING ACTRIl LIGAND TRAPS. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20180125928A1 (enExample) |
| EP (1) | EP3294320A4 (enExample) |
| JP (2) | JP6976859B2 (enExample) |
| KR (1) | KR102640198B1 (enExample) |
| CN (3) | CN122399028A (enExample) |
| AU (2) | AU2016261913B2 (enExample) |
| CA (1) | CA2985777A1 (enExample) |
| HK (1) | HK1251157A1 (enExample) |
| IL (2) | IL284686B2 (enExample) |
| JO (1) | JOP20160092B1 (enExample) |
| MY (1) | MY189601A (enExample) |
| PH (1) | PH12017502079A1 (enExample) |
| TN (1) | TN2017000468A1 (enExample) |
| TW (2) | TWI814187B (enExample) |
| WO (1) | WO2016183280A1 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0618947B1 (pt) | 2005-11-23 | 2022-07-19 | Acceleron Pharma Inc | Polipeptídeo actriia que se liga à ativina, polinucleotídeo isolado, polinucleotídeo recombinante, métodopara preparar um polipeptídeo actriia que se liga à ativina, preparação farmacêutica e uso de uma proteína de fusão actriia-fc para promover o crescimento ósseo e inibir a ressorção óssea |
| US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| DK3750552T5 (da) | 2008-08-14 | 2024-08-26 | Acceleron Pharma Inc | Gdf-fælder |
| MX355042B (es) | 2009-06-08 | 2018-04-02 | Acceleon Pharma Inc | Metodos para aumentar adipositos termogenicos. |
| CN107267520A (zh) | 2009-06-12 | 2017-10-20 | 阿塞勒隆制药公司 | 截短的actriib‑fc融合蛋白 |
| ES2658292T3 (es) | 2009-11-17 | 2018-03-09 | Acceleron Pharma, Inc. | Proteínas ActRIIB y variantes y usos de las mismas con respecto a la inducción de la utrofina para el tratamiento de la distrofia muscular |
| US9809636B2 (en) | 2012-04-06 | 2017-11-07 | Acceleron Pharma Inc. | Methods for increasing red blood cell levels comprising administering BMP9 |
| RU2678117C2 (ru) | 2012-11-02 | 2019-01-23 | Селджин Корпорейшн | Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений |
| CN114699529A (zh) | 2014-06-13 | 2022-07-05 | 阿塞勒隆制药公司 | 用于治疗溃疡的方法和组合物 |
| MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
| EP3227675B1 (en) | 2014-12-03 | 2023-03-15 | Celgene Corporation | Activin-actrii antagonists and uses for treating myelodysplastic syndrome |
| MA41119A (fr) | 2014-12-03 | 2017-10-10 | Acceleron Pharma Inc | Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique |
| EP3298034A4 (en) | 2015-05-20 | 2019-02-13 | Celgene Corporation | IN VITRO CELL CULTURE PROCEDURE FOR BETA THALASSEMIA BY MEANS OF ACTIVIN TYPE II RECEPTOR LIGANDS |
| EP3370754B1 (en) | 2015-11-04 | 2026-04-29 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating ineffective erythropoiesis |
| JP7072507B2 (ja) | 2015-11-23 | 2022-05-20 | アクセルロン ファーマ インコーポレイテッド | 眼の障害を処置するための方法 |
| AU2017296040C1 (en) | 2016-07-15 | 2023-06-22 | Acceleron Pharma Inc. | Compositions and methods for treating pulmonary hypertension |
| LT3490582T (lt) | 2016-07-27 | 2024-07-25 | Acceleron Pharma Inc. | Kompozicijos, skirtos naudoti gydant mielofibrozę |
| CA3043184A1 (en) | 2016-11-10 | 2018-05-17 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
| WO2018231905A1 (en) * | 2017-06-14 | 2018-12-20 | Celgene Corporation | Methods for treating myeloproliferative neoplasm-associated myelofibrosis and anemia |
| EP3706777B1 (en) | 2017-11-09 | 2024-05-22 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
| IL320014A (en) | 2018-01-12 | 2025-06-01 | Keros Therapeutics Inc | Activin receptor type iib variants and methods of use thereof |
| WO2019213016A1 (en) | 2018-04-30 | 2019-11-07 | The Children's Hospital Of Philadelphia | Methods of improving anemias by combining agents |
| IL278546B2 (en) | 2018-05-09 | 2026-03-01 | Keros Therapeutics Inc | Activin receptor type IIA variants and methods of using them |
| JP7663502B2 (ja) * | 2018-10-31 | 2025-04-16 | セルジーン コーポレイション | 環状鉄芽球が見られる対象における非常に低リスク、低リスクまたは中程度のリスクの骨髄異形成症候群による貧血の、アクチビン－ａｃｔｒｉｉリガンドトラップを用いた治療 |
| CN114302882A (zh) | 2019-07-19 | 2022-04-08 | 威佛（国际）股份公司 | 用于治疗输血依赖型β-地中海贫血（tdt）的膜铁转运蛋白抑制剂 |
| CN112924684B (zh) * | 2019-12-05 | 2022-07-29 | 中国科学院大连化学物理研究所 | 用于区分抑郁症和非抑郁症的生物标志物和包括其的诊断试剂盒 |
| EP4121088A4 (en) | 2020-03-20 | 2024-07-03 | Keros Therapeutics, Inc. | Methods of using activin receptor type iib variants |
| EP4121078A4 (en) | 2020-03-20 | 2024-08-14 | Keros Therapeutics, Inc. | ACTIVIN RECEPTOR TYPE II CHIMERAS AND METHODS OF USE THEREOF |
| US20230181690A1 (en) * | 2020-04-13 | 2023-06-15 | Celgene Corporation | Methods for treating anemia using an actriib ligand trap and fedratinib |
| US20230174620A1 (en) | 2020-04-28 | 2023-06-08 | Acceleron Pharma Inc. | Actrii proteins and use in treating post-capillary pulmonary hypertension |
| US12186370B1 (en) | 2020-11-05 | 2025-01-07 | Celgene Corporation | ACTRIIB ligand trap compositions and uses thereof |
| US20230270821A1 (en) * | 2020-11-06 | 2023-08-31 | Acceleron Pharma Inc. | Formulations comprising actrii polypeptide variants |
| US20240181007A1 (en) * | 2021-01-08 | 2024-06-06 | Acceleron Pharma Inc. | Compositions and methods for treating pulmonary hypertension |
| WO2022157185A1 (en) | 2021-01-20 | 2022-07-28 | Vifor (International) Ag | Ferroportin-inhibitors for the use in the treatment of myelodysplastic syndromes (mds) |
| CN121511085A (zh) | 2023-06-26 | 2026-02-10 | 威佛（国际）股份公司 | 用于遗传性血色素沉着病（hh）的治疗的膜铁转运蛋白抑制剂 |
| WO2025122830A1 (en) * | 2023-12-08 | 2025-06-12 | Keros Therapeutics, Inc. | Methods of using activin receptor type ii signaling inhibitors |
| WO2026041650A1 (en) | 2024-08-20 | 2026-02-26 | Vifor (International) Ag | Ferroportin-inhibitors for the use in the treatment of lupus nephritis |
| WO2026096847A1 (en) * | 2024-11-01 | 2026-05-07 | Bristol-Myers Squibb Company | Methods of regulating inflammation and autophagy using actriib ligand traps |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4247A (en) * | 1845-11-01 | Jordan l | ||
| US6231880B1 (en) * | 1997-05-30 | 2001-05-15 | Susan P. Perrine | Compositions and administration of compositions for the treatment of blood disorders |
| CA2672758C (en) * | 2006-12-18 | 2019-07-30 | Acceleron Pharma Inc. | Activin-actrii antagonists and uses for increasing red blood cell levels |
| EP2315602A4 (en) * | 2008-06-26 | 2011-11-02 | Acceleron Pharma Inc | METHOD OF DOSING AN ACTRIIB ANTAGONIST AND MONITORING TREATED PATIENTS |
| DK3750552T5 (da) * | 2008-08-14 | 2024-08-26 | Acceleron Pharma Inc | Gdf-fælder |
| EP3202459B1 (en) * | 2009-09-09 | 2021-04-14 | Acceleron Pharma Inc. | Actriib antagonists and dosing and uses thereof for treating obesity or type 2 diabetes by regulating body fat content |
| DK3520805T3 (da) * | 2011-10-17 | 2021-04-19 | Acceleron Pharma Inc | Sammensætninger til behandling af myelofibrose |
| BR112014024358A8 (pt) * | 2012-03-30 | 2018-01-23 | Shire Human Genetic Therapies | administração subcutânea de iduronato-2-sulfatase |
| CA2889209C (en) * | 2012-10-24 | 2023-08-22 | Celgene Corporation | Biomarker for use in treating anemia |
| JP6401172B2 (ja) * | 2012-10-24 | 2018-10-10 | セルジーン コーポレイション | 貧血の治療方法 |
| ES2708948T3 (es) * | 2012-11-27 | 2019-04-12 | Childrens Medical Ct Corp | Elementos reguladores distales de bcl11a como dianas para la reinducción de la hemoglobina fetal |
-
2016
- 2016-05-12 TW TW110148304A patent/TWI814187B/zh active
- 2016-05-12 CA CA2985777A patent/CA2985777A1/en active Pending
- 2016-05-12 JO JOP/2016/0092A patent/JOP20160092B1/ar active
- 2016-05-12 AU AU2016261913A patent/AU2016261913B2/en active Active
- 2016-05-12 CN CN202610488096.3A patent/CN122399028A/zh active Pending
- 2016-05-12 CN CN201680041002.2A patent/CN107847562A/zh active Pending
- 2016-05-12 KR KR1020177035838A patent/KR102640198B1/ko active Active
- 2016-05-12 US US15/573,177 patent/US20180125928A1/en not_active Abandoned
- 2016-05-12 JP JP2017559025A patent/JP6976859B2/ja not_active Expired - Fee Related
- 2016-05-12 TW TW105114763A patent/TWI762444B/zh active
- 2016-05-12 TN TNP/2017/000468A patent/TN2017000468A1/en unknown
- 2016-05-12 IL IL284686A patent/IL284686B2/en unknown
- 2016-05-12 EP EP16793499.1A patent/EP3294320A4/en active Pending
- 2016-05-12 CN CN202610574267.4A patent/CN122537533A/zh active Pending
- 2016-05-12 WO PCT/US2016/031999 patent/WO2016183280A1/en not_active Ceased
- 2016-05-12 HK HK18110608.3A patent/HK1251157A1/zh unknown
- 2016-05-12 MY MYPI2017704290A patent/MY189601A/en unknown
-
2017
- 2017-11-08 IL IL255527A patent/IL255527B/en unknown
- 2017-11-16 PH PH12017502079A patent/PH12017502079A1/en unknown
-
2021
- 2021-08-13 JP JP2021131870A patent/JP2021191755A/ja active Pending
- 2021-10-29 AU AU2021258087A patent/AU2021258087B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20180125928A1 (en) | 2018-05-10 |
| TWI814187B (zh) | 2023-09-01 |
| AU2016261913B2 (en) | 2021-08-12 |
| CA2985777A1 (en) | 2016-11-17 |
| HK1251157A1 (zh) | 2019-01-25 |
| KR20180006437A (ko) | 2018-01-17 |
| MY189601A (en) | 2022-02-18 |
| AU2021258087B2 (en) | 2023-04-27 |
| EP3294320A1 (en) | 2018-03-21 |
| JOP20160092B1 (ar) | 2023-03-28 |
| IL255527A (en) | 2018-01-31 |
| CN122537533A (zh) | 2026-08-11 |
| TWI762444B (zh) | 2022-05-01 |
| IL284686B2 (en) | 2023-05-01 |
| TW202231294A (zh) | 2022-08-16 |
| NZ737043A (en) | 2025-02-28 |
| KR102640198B1 (ko) | 2024-02-23 |
| CN122399028A (zh) | 2026-07-17 |
| TW201709927A (zh) | 2017-03-16 |
| PH12017502079A1 (en) | 2018-06-11 |
| IL255527B (en) | 2021-07-29 |
| IL284686B (en) | 2023-01-01 |
| JP6976859B2 (ja) | 2021-12-08 |
| JP2018520094A (ja) | 2018-07-26 |
| CN107847562A (zh) | 2018-03-27 |
| JP2021191755A (ja) | 2021-12-16 |
| IL284686A (en) | 2021-08-31 |
| EP3294320A4 (en) | 2018-12-26 |
| WO2016183280A1 (en) | 2016-11-17 |
| AU2021258087A1 (en) | 2021-11-25 |
| AU2016261913A1 (en) | 2017-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12017502079A1 (en) | Treatment of beta-thalassemia using actrii ligand traps | |
| PH12020550901A1 (en) | Macrocyclic compounds for treating disease | |
| WO2018089669A3 (en) | Immunotherapeutic tumor treatment method | |
| PH12019500214A1 (en) | Substituted thiazolo-pyridine compounds as malt1 inhibitors | |
| MY198613A (en) | Nitrobenzyl derivatives of anti-cancer agents | |
| EA201890146A1 (ru) | СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ | |
| TW201613887A (en) | Antiproliferative compounds and methods of use thereof | |
| SG10201902664RA (en) | Combination therapy for treating cancer | |
| SA519410320B1 (ar) | مركبات فينيل -2-هيدروكسي-أسيتيل أمينو -2-ميثيل-فينيل | |
| MX368903B (es) | Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas. | |
| MA39765A (fr) | Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation | |
| MX381440B (es) | Composicion farmaceutica para tratar colitis ulcerativa. | |
| PH12016502352A1 (en) | Pharmaceutical composition | |
| PH12020550462A1 (en) | Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same | |
| MX2022007315A (es) | Formulaciones de olanzapina de liberacion sostenida. | |
| EA201792264A1 (ru) | Способы лечения воспалительных заболеваний | |
| MX2018014129A (es) | Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato. | |
| MY198753A (en) | Treatment of androgen deprivation therapy associated symptoms | |
| AR104621A1 (es) | TRATAMIENTO DE LA b-TALASEMIA POR EL USO DE TRAMPAS DE LIGANDO ActRII | |
| RU2014107146A (ru) | Способ профилактики канцерогенного действия диэтилнитрозамина у экспериментальных животных | |
| EA201892675A1 (ru) | Фармацевтическая композиция, содержащая этеплирсен | |
| MX2016010919A (es) | 4-bencilsulfonil-2-butenonitrilo. | |
| WO2016164719A3 (en) | Methods used to treat cancer | |
| UA104615U (uk) | Спосіб лікування токсокарозу | |
| HK1240497A1 (en) | Compositions and methods for treatment of prostate carcinoma |